{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:16:07Z","timestamp":1792080967652,"version":"4.4.0"},"reference-count":83,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2009,7]]},"DOI":"10.1016\/j.euroneuro.2009.04.003","type":"journal-article","created":{"date-parts":[[2009,5,4]],"date-time":"2009-05-04T04:48:23Z","timestamp":1241412503000},"page":"520-532","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":118,"title":["Advantages and disadvantages of combination treatment with antipsychotics"],"prefix":"10.1016","volume":"19","author":[{"given":"Guy","family":"Goodwin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Fleischhacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celso","family":"Arango","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Baumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"de Hert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Falkai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shitij","family":"Kapur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Leucht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasmus","family":"Licht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"Naber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"O'Keane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Papakostas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard","family":"Vieta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Zohar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4 Suppl","key":"10.1016\/j.euroneuro.2009.04.003_bib1","first-page":"1","article-title":"Practice guideline for the treatment of patients with bipolar disorder (revision)","volume":"159","author":"American Psychiatric Association","year":"2002","journal-title":"Am. J. Psychiatr."},{"issue":"1","key":"10.1016\/j.euroneuro.2009.04.003_bib2","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.schres.2004.01.016","article-title":"Valproate as an adjunct to antipsychotics for schizophrenia: a systematic review of randomized trials","volume":"70","author":"Basan","year":"2004","journal-title":"Schizophr. Res."},{"issue":"6","key":"10.1016\/j.euroneuro.2009.04.003_bib3","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1055\/s-2004-832687","article-title":"The AGNP-TDM expert group consensus guidelines: Therapeutic Drug Monitoring in psychiatry","volume":"37","author":"Baumann","year":"2004","journal-title":"Pharmacopsychiatry"},{"issue":"2","key":"10.1016\/j.euroneuro.2009.04.003_bib4","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2165\/00002018-200629020-00001","article-title":"Interactions between antiepileptic and antipsychotic drugs","volume":"29","author":"Besag","year":"2006","journal-title":"Drug Safety"},{"issue":"7","key":"10.1016\/j.euroneuro.2009.04.003_bib5","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/sj.mp.4001823","article-title":"A systematic review: antipsychotic augmentation with treatment refractory obsessive\u2013compulsive disorder","volume":"11","author":"Bloch","year":"2006","journal-title":"Mol. Psychiatry"},{"issue":"1\u20133","key":"10.1016\/j.euroneuro.2009.04.003_bib6","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.schres.2006.09.025","article-title":"Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study","volume":"90","author":"Bobes","year":"2007","journal-title":"Schizophr. Res."},{"issue":"4","key":"10.1016\/j.euroneuro.2009.04.003_bib7","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/00004850-200207000-00006","article-title":"Clozapine-treated subjects with treatment-resistant schizophrenia: a systematic review of experimental and observational studies","volume":"17","author":"Brambilla","year":"2002","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.euroneuro.2009.04.003_bib8","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2165\/00003088-200443010-00003","article-title":"Pharmacokinetic factors in the adverse cardiovascular effects of antipsychotic drugs","volume":"43","author":"Brown","year":"2004","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.euroneuro.2009.04.003_bib9","first-page":"S22","article-title":"Cycloset (Quick-Release Bromocriptine Mesylate), a novel centrally acting treatment for type 2 diabetes","volume":"51","author":"Cincotta","year":"2008","journal-title":"Diabetologia"},{"issue":"9","key":"10.1016\/j.euroneuro.2009.04.003_bib10","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1176\/appi.ps.55.9.1006","article-title":"Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients","volume":"55","author":"Citrome","year":"2004","journal-title":"Psychiatr. Serv."},{"issue":"5","key":"10.1016\/j.euroneuro.2009.04.003_bib11","doi-asserted-by":"crossref","first-page":"860","DOI":"10.4088\/JCP.v69n0521","article-title":"Antipsychotic polypharmacy, Part 2: why use 2 antipsychotics when 1 is not good enough?","volume":"69","author":"Correll","year":"2008","journal-title":"J. Clin. Psychiatry"},{"issue":"2","key":"10.1016\/j.euroneuro.2009.04.003_bib12","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/YCO.0b013e3282f53132","article-title":"Tardive dyskinesia and new antipsychotics","volume":"21","author":"Correll","year":"2008","journal-title":"Curr. Opin. Psychiatry"},{"issue":"1\u20133","key":"10.1016\/j.euroneuro.2009.04.003_bib13","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.schres.2006.08.017","article-title":"Does antipsychotic polypharmacy increase the risk for metabolic syndrome?","volume":"89","author":"Correll","year":"2007","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.euroneuro.2009.04.003_bib14","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/schbul\/sbn018","article-title":"Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials","volume":"35","author":"Correll","year":"2009","journal-title":"Schizophr. Bull."},{"issue":"7","key":"10.1016\/j.euroneuro.2009.04.003_bib15","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2165\/00003088-200241070-00001","article-title":"Cytochrome p450 phenotyping\/genotyping in patients receiving antipsychotics\u2014useful aid to prescribing?","volume":"41","author":"Dahl","year":"2002","journal-title":"Clin. Pharmacokinet."},{"issue":"6","key":"10.1016\/j.euroneuro.2009.04.003_bib16","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1176\/appi.ajp.157.6.1019","article-title":"Subjective experience and striatal dopamine D-2 receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone","volume":"157","author":"de Haan","year":"2000","journal-title":"Am. J. Psychiatr."},{"issue":"12","key":"10.1016\/j.euroneuro.2009.04.003_bib17","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.4088\/JCP.v67n1208","article-title":"Treatment with rosuvastatin for severe dyslipidemia in patients with schizophrenia and schizoaffective disorder","volume":"67","author":"De Hert","year":"2006","journal-title":"J. Clin. Psychiatry"},{"issue":"4","key":"10.1016\/j.euroneuro.2009.04.003_bib18","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/13651500600811206","article-title":"Pharmacological treatment of hospitalised schizophrenic patients in Belgium","volume":"10","author":"De Hert","year":"2006","journal-title":"Int. J. Psychiatry Clin. Pract."},{"issue":"2\u20133","key":"10.1016\/j.euroneuro.2009.04.003_bib19","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.psychres.2006.07.012","article-title":"Anticholinergic use in hospitalised schizophrenic patients in Belgium","volume":"152","author":"De Hert","year":"2007","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.euroneuro.2009.04.003_bib20","doi-asserted-by":"crossref","DOI":"10.1186\/1471-244X-7-40","article-title":"Atypical antipsychotics in bipolar disorder: systematic review of randomised trials","volume":"7","author":"Derry","year":"2007","journal-title":"Bmc Psychiatry"},{"issue":"5","key":"10.1016\/j.euroneuro.2009.04.003_bib21","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/s00406-006-0664-4","article-title":"ABC drug transporter at the blood-brain barrier\u2014effects on drug metabolism and drug response","volume":"256","author":"Ebinger","year":"2006","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"1","key":"10.1016\/j.euroneuro.2009.04.003_bib22","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.schres.2005.01.015","article-title":"Trends in the pharmacological treatment of patients with schizophrenia over a 12\u00a0year observation period","volume":"77","author":"Edlinger","year":"2005","journal-title":"Schizophr. Res."},{"issue":"6","key":"10.1016\/j.euroneuro.2009.04.003_bib23","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1053\/comp.2001.27898","article-title":"Insight and treatment outcome in obsessive\u2013compulsive disorder","volume":"42","author":"Eisen","year":"2001","journal-title":"Compr. Psychiatry"},{"issue":"supplement 2","key":"10.1016\/j.euroneuro.2009.04.003_bib24","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0920-9964(08)70150-6","article-title":"Effectiveness of antipsychotic drugs in first episode schizophrenia and schizophreniform disorder","volume":"102","author":"Fleischhacker","year":"2008","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2009.04.003_bib25","doi-asserted-by":"crossref","first-page":"S114","DOI":"10.1016\/j.eurpsy.2008.01.784","article-title":"Weight change on aripiprazole\u2013clozapine combination in schizophrenic patients with weight gain and suboptimal response on clozapine: 16-week double-blind study","volume":"23","author":"Fleischhacker","year":"2008","journal-title":"Eur. Psychiatr."},{"issue":"7","key":"10.1016\/j.euroneuro.2009.04.003_bib26","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.4088\/JCP.v69n0717","article-title":"Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics","volume":"69","author":"Fraguas","year":"2008","journal-title":"J. Clin. Psychiatry"},{"issue":"11","key":"10.1016\/j.euroneuro.2009.04.003_bib27","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.biopsych.2005.04.056","article-title":"The Maudsley Bipolar Disorder Project: executive dysfunction in bipolar disorder I and its clinical correlates","volume":"58","author":"Frangou","year":"2005","journal-title":"Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.euroneuro.2009.04.003_bib28","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1600-0447.2005.00612.x","article-title":"An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia","volume":"113","author":"Henderson","year":"2006","journal-title":"Acta Psychiatr. Scand."},{"issue":"4","key":"10.1016\/j.euroneuro.2009.04.003_bib29","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/00004714-199408000-00011","article-title":"Elevated levels of clozapine in serum after addition of fluvoxamine","volume":"14","author":"Hiemke","year":"1994","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2009.04.003_bib30","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/13651500701388468","article-title":"Anxiety and OC spectrum disorders over life cycle","volume":"11","author":"Hollander","year":"2007","journal-title":"Int. J. Psychiatry Clin. Pract."},{"issue":"5","key":"10.1016\/j.euroneuro.2009.04.003_bib31","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1056\/NEJMoa053222","article-title":"Clozapine alone versus clozapine and risperidone with refractory schizophrenia","volume":"354","author":"Honer","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.euroneuro.2009.04.003_bib32","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1185\/030079903125002865","article-title":"Hyperprolactinaemia and antipsychotic therapy in schizophrenia","volume":"20","author":"Hummer","year":"2004","journal-title":"Curr. Med. Res. Opin."},{"issue":"1","key":"10.1016\/j.euroneuro.2009.04.003_bib33","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1176\/appi.ajp.162.1.162","article-title":"Osteoporosis in patients with schizophrenia","volume":"162","author":"Hummer","year":"2005","journal-title":"Am. J. Psychiatr."},{"issue":"1","key":"10.1016\/j.euroneuro.2009.04.003_bib34","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00210-003-0819-z","article-title":"Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms","volume":"369","author":"Ingelman-Sundberg","year":"2004","journal-title":"Naunyn-Schmiedebergs Archives of Pharmacology"},{"issue":"1","key":"10.1016\/j.euroneuro.2009.04.003_bib35","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1176\/appi.ajp.162.1.130","article-title":"Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial","volume":"162","author":"Josiassen","year":"2005","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.euroneuro.2009.04.003_bib36","first-page":"25","article-title":"An evidence-based strategy for remission in schizophrenia","volume":"69","author":"Kane","year":"2008","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.04.003_bib37","first-page":"5","article-title":"Expert consensus guideline series\u2014optimizing pharmacologic treatment of psychotic disorders\u2013Introduction: Methods, commentary, and summary","volume":"64","author":"Kane","year":"2003","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.04.003_bib38","first-page":"S85","article-title":"Linking dopamine to salience to the subjective experience of patients with psychosis and antipsychotics","volume":"9","author":"Kapur","year":"2006","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"Suppl 4","key":"10.1016\/j.euroneuro.2009.04.003_bib39","first-page":"33","article-title":"Antipsychotics in the treatment of mood disorders and risk of tardive dyskinesia","volume":"61","author":"Keck","year":"2000","journal-title":"J. Clin. Psychiatry"},{"issue":"4","key":"10.1016\/j.euroneuro.2009.04.003_bib40","first-page":"581","article-title":"A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression","volume":"69","author":"Kennedy","year":"2001","journal-title":"Am. J. Hum. Genet."},{"issue":"11","key":"10.1016\/j.euroneuro.2009.04.003_bib41","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1038\/sj.npp.1301361","article-title":"Psychiatric diagnosis and clinical trial completion rates: analysis of the FDA SBA reports","volume":"32","author":"Khan","year":"2007","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"10.1016\/j.euroneuro.2009.04.003_bib42","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/sj.mp.4001494","article-title":"Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response","volume":"9","author":"Kirchheiner","year":"2004","journal-title":"Mol. Psychiatry"},{"issue":"3","key":"10.1016\/j.euroneuro.2009.04.003_bib43","doi-asserted-by":"crossref","first-page":"385","DOI":"10.4088\/JCP.v69n0307","article-title":"Antipsychotic-induced hyperprolactinemia inhibits the hypothalamo\u2013pituitary\u2013gonadal axis and reduces bone mineral density in male patients with schizophrenia","volume":"69","author":"Kishimoto","year":"2008","journal-title":"J. Clin. Psychiatry"},{"issue":"5","key":"10.1016\/j.euroneuro.2009.04.003_bib44","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/JCP.0b013e318185e735","article-title":"Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive\u2013compulsive disorder: a double-blind, randomized, placebo-controlled study","volume":"28","author":"Kordon","year":"2008","journal-title":"J. Clin. Psychopharmacol."},{"issue":"9657","key":"10.1016\/j.euroneuro.2009.04.003_bib45","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis","volume":"373","author":"Leucht","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2009.04.003_bib46","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1192\/bjp.170.3.264","article-title":"Generalisability of results from randomised drug trials\u2014a trial on antimanic treatment","volume":"170","author":"Licht","year":"1997","journal-title":"Br. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.euroneuro.2009.04.003_bib47","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.euroneuro.2007.06.003","article-title":"A review on the impact of P-glycoprotein on the penetration of drugs into the brain. Focus on psychotropic drugs","volume":"18","author":"Linnet","year":"2008","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.euroneuro.2009.04.003_bib48","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.clpt.2003.09.012","article-title":"Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance","volume":"75","author":"Marzolini","year":"2004","journal-title":"Clin. Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.euroneuro.2009.04.003_bib49","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2165\/00003088-200746050-00001","article-title":"Clinical pharmacokinetics of atypical antipsychotics\u2014a critical review of the relationship between plasma concentrations and clinical response","volume":"46","author":"Mauri","year":"2007","journal-title":"Clin. Pharmacokinet."},{"issue":"1\u20133","key":"10.1016\/j.euroneuro.2009.04.003_bib50","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.schres.2007.01.013","article-title":"Bone mineral density changes over a year in young females with schizophrenia: relationship to medication and endocrine variables","volume":"93","author":"Meaney","year":"2007","journal-title":"Schizophr. Res."},{"issue":"9","key":"10.1016\/j.euroneuro.2009.04.003_bib51","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.euroneuro.2008.06.003","article-title":"A regulatory Apologia\u2014a review of placebo-controlled studies in regulatory submissions of new-generation antidepressants","volume":"18","author":"Melander","year":"2008","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"2","key":"10.1016\/j.euroneuro.2009.04.003_bib52","doi-asserted-by":"crossref","first-page":"S106","DOI":"10.1016\/S0893-133X(99)00046-9","article-title":"The role of serotonin in antipsychotic drug action","volume":"21","author":"Meltzer","year":"1999","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.euroneuro.2009.04.003_bib53","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1176\/ajp.2007.164.4.630","article-title":"Adverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D-2 receptors: a PET study in schizophrenia","volume":"164","author":"Mizrahi","year":"2007","journal-title":"Am. J. Psychiatry"},{"issue":"7","key":"10.1016\/j.euroneuro.2009.04.003_bib54","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.pnpbp.2003.09.006","article-title":"Amisulpride: limbic specificity and the mechanism of antipsychotic atypicality","volume":"27","author":"Moller","year":"2003","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.euroneuro.2009.04.003_bib55","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/00004714-200004000-00012","article-title":"Valproate as an adjunct to neuroleptic medication for the treatment of acute episodes of mania: a prospective, randomized, double-blind, placebo-controlled, multicenter study. European Valproate Mania Study Group","volume":"20","author":"Muller-Oerlinghausen","year":"2000","journal-title":"J. Clin. Psychopharmacol."},{"issue":"7","key":"10.1016\/j.euroneuro.2009.04.003_bib56","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1211\/jpp.58.7.0001","article-title":"Role of CYP pharmacogenetics and drug\u2013drug interactions in the efficacy and safety of atypical and other antipsychotic agents","volume":"58","author":"Murray","year":"2006","journal-title":"J. Pharm. Pharmacol."},{"issue":"1","key":"10.1016\/j.euroneuro.2009.04.003_bib57","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1016\/j.euroneuro.2008.08.009","article-title":"Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD","volume":"19","author":"Papakostas","year":"2009","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"6","key":"10.1016\/j.euroneuro.2009.04.003_bib58","doi-asserted-by":"crossref","first-page":"826","DOI":"10.4088\/JCP.v68n0602","article-title":"Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis","volume":"68","author":"Papakostas","year":"2007","journal-title":"J. Clin. Psychiatry"},{"issue":"2","key":"10.1016\/j.euroneuro.2009.04.003_bib59","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/JCP.0b013e318036bfbb","article-title":"Augmentation with a second antipsychotic in patients with schizophrenia who partially respond to clozapine\u2014a meta-analysis","volume":"27","author":"Paton","year":"2007","journal-title":"J. Clin. Psychopharmacol."},{"issue":"6","key":"10.1016\/j.euroneuro.2009.04.003_bib60","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1192\/bjp.bp.107.042895","article-title":"High-dose and combination antipsychotic prescribing in acute adult wards in the UK: the challenges posed by p.r.n. prescribing","volume":"192","author":"Paton","year":"2008","journal-title":"Br. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.euroneuro.2009.04.003_bib61","doi-asserted-by":"crossref","first-page":"509","DOI":"10.4088\/JCP.v67n0401","article-title":"Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials","volume":"67","author":"Perlis","year":"2006","journal-title":"J. Clin. Psychiatry"},{"issue":"2","key":"10.1016\/j.euroneuro.2009.04.003_bib62","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/00004714-199004000-00003","article-title":"Central-nervous-system toxicity of tricyclic antidepressants\u2014phenomenology, course, risk-factors, and role of therapeutic drug-monitoring","volume":"10","author":"Preskorn","year":"1990","journal-title":"J. Clin. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.euroneuro.2009.04.003_bib63","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1139\/jpn.0312","article-title":"Interactions between the cytochrome P450 system and the second-generation antipsychotics","volume":"28","author":"Prior","year":"2003","journal-title":"J. Psychiatry Neurosci."},{"issue":"11","key":"10.1016\/j.euroneuro.2009.04.003_bib64","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1038\/sj.npp.1301113","article-title":"Effects of risperidone augmentation in patients with treatment-resistant depression: results of open-label treatment followed by double-blind continuation","volume":"31","author":"Rapaport","year":"2006","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.euroneuro.2009.04.003_bib65","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0924-9338(99)80713-5","article-title":"Polypharmacy in psychiatric treatment. Patterns of psychotropic drug use in Austrian psychiatric clinics","volume":"14","author":"Rittmannsberger","year":"1999","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.04.003_bib66","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1600-0447.2007.01056.x","article-title":"Adjunctive treatment of acute mania: a clinical overview","volume":"116","author":"Sachs","year":"2007","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.euroneuro.2009.04.003_bib67","first-page":"S372","article-title":"Quick release bromocriptine (Cycloset (TM)) improves glycaemic control in patients with diabetes failing metformin\/sulfonylurea combination therapy","volume":"51","author":"Scranton","year":"2008","journal-title":"Diabetologia"},{"key":"10.1016\/j.euroneuro.2009.04.003_bib68","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1192\/bjp.171.6.569","article-title":"Sulpiride augmentation in people with schizophrenia partially responsive to clozapine\u2014a double-blind, placebo-controlled study","volume":"171","author":"Shiloh","year":"1997","journal-title":"Br. J. Psychiatry"},{"issue":"9","key":"10.1016\/j.euroneuro.2009.04.003_bib69","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1176\/appi.ajp.2007.06071075","article-title":"Adjunctive treatment with a dopamine partial agonist, aripiprazole, for anti psychotic-induced hyperprolactinemia: a placebo-controlled trial","volume":"164","author":"Shim","year":"2007","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.euroneuro.2009.04.003_bib70","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1600-0447.2006.00912.x","article-title":"Acute bipolar mania: a systematic review and meta-analysis of co-therapy vs. monotherapy","volume":"115","author":"Smith","year":"2007","journal-title":"Acta Psychiatr. Scand."},{"issue":"1","key":"10.1016\/j.euroneuro.2009.04.003_bib71","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1742-7843.2007.00017.x","article-title":"Metabolic drug interactions with newer antipsychotics: a comparative review","volume":"100","author":"Spina","year":"2007","journal-title":"Basic & Clinical Pharmacology & Toxicology"},{"key":"10.1016\/j.euroneuro.2009.04.003_bib83","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1176\/appi.ajp.2008.08020189","article-title":"Maintenance Treatment for Patients With Bipolar I Disorder: Results From a North American Study of Quetiapine in Combination With Lithium or Divalproex (Trial 127)","volume":"166","author":"Suppes","year":"2009","journal-title":"American Journal Psychiatry in Advance"},{"key":"10.1016\/j.euroneuro.2009.04.003_bib72","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1192\/bjp.184.4.337","article-title":"Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone","volume":"184","author":"Tohen","year":"2004","journal-title":"Br. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.euroneuro.2009.04.003_bib73","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1192\/bjp.bp.107.041301","article-title":"Olanzapine plus carbamazepine v. carbamazepine alone in treating manic episodes","volume":"192","author":"Tohen","year":"2008","journal-title":"Br. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.euroneuro.2009.04.003_bib74","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1600-0447.2008.01204.x","article-title":"Weight gain in bipolar disorder: pharmacological treatment as a contributing factor","volume":"118","author":"Torrent","year":"2008","journal-title":"Acta Psychiatr. Scand."},{"issue":"1","key":"10.1016\/j.euroneuro.2009.04.003_bib75","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1176\/appi.ajp.163.1.28","article-title":"Evaluation of outcomes with citalopram for depression using measurement-based care in STAR\u204eD: implications for clinical practice","volume":"163","author":"Trivedi","year":"2006","journal-title":"Am. J. Psychiatry"},{"issue":"1\u20132","key":"10.1016\/j.euroneuro.2009.04.003_bib76","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jad.2007.05.009","article-title":"Olanzapine monotherapy and olanzapine combination therapy in the treatment of mania: 12-week results from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) observational study","volume":"106","author":"Vieta","year":"2008","journal-title":"J. Affect. Disord."},{"issue":"3","key":"10.1016\/j.euroneuro.2009.04.003_bib77","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jad.2008.06.001","article-title":"Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126)","volume":"109","author":"Vieta","year":"2008","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2009.04.003_bib78","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1016\/S0924-977X(07)70102-5","article-title":"Double-blind, randomized, placebo-controlled addition of quetiapine in non-refractory OCD patients","volume":"17","author":"Vulink","year":"2007","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"4","key":"10.1016\/j.euroneuro.2009.04.003_bib79","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00213-006-0437-9","article-title":"Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein","volume":"187","author":"Wang","year":"2006","journal-title":"Psychopharmacology"},{"issue":"7","key":"10.1016\/j.euroneuro.2009.04.003_bib80","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/hup.869","article-title":"Open-label steady-state pharmacokinetic drug interaction study on co-administered quetiapine fumarate and divalproex sodium in patients with schizophrenia, schizoaffective disorder, or bipolar disorder","volume":"22","author":"Winter","year":"2007","journal-title":"Human Psychopharmacology-Clinical and Experimental"},{"issue":"1\u20133","key":"10.1016\/j.euroneuro.2009.04.003_bib81","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jad.2006.08.017","article-title":"Pharmacological treatment of acute mania in psychiatric in-patients between 1994 and 2004","volume":"99","author":"Wolfsperger","year":"2007","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2009.04.003_bib82","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1192\/bjp.182.2.141","article-title":"Mood stabilisers plus risperidone or placebo in the treatment of acute mania\u2014international, double-blind, randomised controlled trial","volume":"182","author":"Yatham","year":"2003","journal-title":"Br. J, Psychiatry"}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X09000972?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X09000972?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:49:34Z","timestamp":1760377774000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X09000972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7]]},"references-count":83,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["S0924977X09000972"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2009.04.003","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2009,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advantages and disadvantages of combination treatment with antipsychotics","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2009.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}